Time-course changes in plasma endothelin-1 and its effects on the mesenteric arterial bed in streptozotocin-induced diabetic rats

Diabetes, Obesity and Metabolism

Volumn 2, Issue 1, 2000, Pages 47-55

  Makino, A ^a   Kamata, K ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Diabetes; Endothelin 1; Endothelium; Glucose; Mesenteric arterial bed; Rat; Streptozotocin

Indexed keywords

CHOLESTEROL; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; GLUCOSE; INSULIN; STREPTOZOCIN; SUCCINYLENDOTHELIN 1 [8-21][9 GLUTAMIC ACID 11,15 ALANINE]; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY CONSTRICTION; ARTICLE; BLOOD VESSEL REACTIVITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INCUBATION TIME; LONG TERM CARE; MALE; MESENTERIC ARTERY; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; RAT; TIME; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE; VASOCONSTRICTION; VASODILATATION;

EID: 0034522451     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2000.00024.x     Document Type: Article

References (49)

1. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
2. Endothelin, a potent vasoconstrictor, is a vascular smooth muscle mitogen
3. Increased plasma concentration of endothelin-1 and big endothelin-1 in acute myocardial infarction
4. Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension
5. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease?
6. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension
7. Endothelin peptide and receptors in human atherosclerotic coronary artery and aorta
8. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure: Marked increase in endothelin-1 production in the failing heart
9. Elevated endothelin-1 in heart failure and loss of normal response to postural change
10. Increased plasma endothelin levels in patients with insulin-dependent diabetes mellitus and end-stage vascular complications
11. PAI-1 and factor VII activity are higher in IDDM patients with microalbuminuria
12. Plasma endothelin levels and vascular effects of intravenous L-arginine infusion in subjects with uncomplicated insulin-dependent diabetes mellitus
13. Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells
14. Effect of glucose and insulin on immunoreactive endothelin-1 release from cultured porcine aortic endothelial cells
15. Insulin stimulates endothelin binding and action on cultured vascular smooth muscle cells
16. High-glucose-induced mesangial cell altered contractility: Role of the polyol pathway
17. Elevated plasma endothelin-1 level in streptozotocin-induced diabetic rats and responsiveness of the mesenteric arterial beds to endothelin-1
18. An O-toluidine method for body-fluid glucose determination
19. The effect of sympathetic nerve stimulation on vasoconstrictor responses in perfused mesenteric blood vessels of the rat
20. Possible existence of novel endothelium-derived relaxing factor in the endothelium of rat mesenteric arterial bed
21. 1-adrenoceptor agonist
22. Endothelins as cardiovascular peptide
23. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia
24. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor
25. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor
26. Superoxide dismutase recovers altered endothelium-dependent relaxation in diabetic rat aorta
27. Changes in superoxide dismutase mRNA expression by streptozotocin-induced diabetes
28. Pathogenetic effects of advanced glycosylation: Biochemical, biologic and clinical implications for diabetes and aging
29. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins
30. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats
31. Advanced glycation end product-induced activation of NF-κB is suppressed by α-lipoic acid in cultured endothelial cells
32. 2, but not noradrenaline, of aortae from rats with streptozotocin-induced diabetes mellitus
33. Effects of chronic diabetes on the responsiveness to Endothelin-1 and other agents of rat atria and thoracic aorta
34. Impaired contraction and relaxation in the aorta of streptozotocin-diabetic rats
35. Protein kinase C-mediated contractile responses of arteries from diabetic rats
36. Enhanced vascular α-adrenergic neuroeffector system in diabetes: Importance of calcium
37. 1 agonist-induced vasoconstriction in diabetes
38. Prevention by insulin treatment of endothelial dysfunction but not enhanced noradrenalin-induced contractility in mesenteric resistance arteries from streptozotocin-induced diabetic rats
39. Vascular contraction induced by activation of membrane calcium ion channels is enhanced in streptozotocin-diabetes
40. The effects of hypertension and diabetes mellitus on the vascular reactivity of resistance arteries
41. Responses of the isolated perfused mesenteric vasculature from diabetic rats: The significance of appropriate control tissues
42. Glucose-induced vascular smooth muscle dysfunction: The role of protein kinase C
43. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor
44. B-receptor stimulation on arterial, venous and capillary functions in cat skeletal muscle
45. Endothelin-1 and -3 cause endothelium-dependent hyperpolarization in the rat mesenteric artery
46. B and receptors cause vasoconstriction of human resistance and capacitance vessens in vivo
47. Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries
48. Enhanced coronary vasoconstriction to endothelin-B-receptor activation in experimental congestive heart failure
49. Endothelin and calcium antagonists in the skin microcirculation of patients with coronary artery disease